NASDAQ:TELO Telomir Pharmaceuticals (TELO) Stock Price, News & Analysis $1.84 +0.01 (+0.55%) Closing price 04:00 PM EasternExtended Trading$1.82 -0.02 (-0.82%) As of 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Telomir Pharmaceuticals Stock (NASDAQ:TELO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get TELO alerts:Sign Up Key Stats Today's Range$1.77▼$1.8450-Day Range$1.13▼$2.2952-Week Range$1.12▼$8.40Volume221,494 shsAverage Volume1.43 million shsMarket Capitalization$54.76 millionP/E RatioN/ADividend YieldN/APrice Target$15.00Consensus RatingStrong Buy Company Overview Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland. Read More Telomir Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreTELO MarketRank™: Telomir Pharmaceuticals scored higher than 58% of companies evaluated by MarketBeat, and ranked 826th out of 1,841 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingTelomir Pharmaceuticals has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageTelomir Pharmaceuticals has received no research coverage in the past 90 days.Read more about Telomir Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Telomir Pharmaceuticals are expected to grow in the coming year, from ($0.40) to ($0.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Telomir Pharmaceuticals is -4.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Telomir Pharmaceuticals is -4.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTelomir Pharmaceuticals has a P/B Ratio of 92.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Telomir Pharmaceuticals' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.71% of the float of Telomir Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTelomir Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Telomir Pharmaceuticals has recently decreased by 8.28%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTelomir Pharmaceuticals does not currently pay a dividend.Dividend GrowthTelomir Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.71% of the float of Telomir Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTelomir Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Telomir Pharmaceuticals has recently decreased by 8.28%, indicating that investor sentiment is improving significantly. News and Social Media1.1 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Telomir Pharmaceuticals this week, compared to 0 articles on an average week.Search Interest18 people have searched for TELO on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat Follows6 people have added Telomir Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Telomir Pharmaceuticals insiders have not sold or bought any company stock.Read more about Telomir Pharmaceuticals' insider trading history. Receive TELO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Telomir Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address TELO Stock News HeadlinesTelomir Pharmaceuticals Announces Promising Preclinical ResultsJuly 26, 2025 | theglobeandmail.comTelomir Pharmaceuticals stock surges on promising Progeria treatment resultsJuly 25, 2025 | investing.comElon Set to Shock the World on July 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believes will be Elon’s greatest invention ever… Yes, even bigger than Tesla or SpaceX.August 6 at 2:00 AM | Brownstone Research (Ad)TELO Announces Another Important BreakthroughJuly 25, 2025 | finance.yahoo.comTelomir Pharmaceuticals Skyrockets 150% on Breakthrough Preclinical Cancer ResultsJuly 18, 2025 | msn.comTelomir Pharmaceuticals stock soars after promising cancer treatment dataJuly 18, 2025 | investing.comTelomir Pharma Jumps In After-Hours Trading After Drug Reverses Damage In Progeria Cells; Retail Eyes Bigger GainsJuly 18, 2025 | msn.comTelomir says data show Telomir-1 reversed epigenetic silencingJuly 17, 2025 | msn.comSee More Headlines TELO Stock Analysis - Frequently Asked Questions How have TELO shares performed this year? Telomir Pharmaceuticals' stock was trading at $4.12 at the beginning of the year. Since then, TELO shares have decreased by 55.3% and is now trading at $1.84. How were Telomir Pharmaceuticals' earnings last quarter? Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) announced its earnings results on Monday, May, 12th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.03. When did Telomir Pharmaceuticals IPO? Telomir Pharmaceuticals (TELO) raised $7 million in an initial public offering on Friday, February 9th 2024. The company issued 1,000,000 shares at $7.00 per share. Kingswood Investments acted as the underwriter for the IPO. Who are Telomir Pharmaceuticals' major shareholders? Telomir Pharmaceuticals' top institutional shareholders include Y Intercept Hong Kong Ltd (0.22%). How do I buy shares of Telomir Pharmaceuticals? Shares of TELO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/12/2025Today8/06/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TELO Previous SymbolNASDAQ:TELO CIK1971532 Webtelomirpharma.com Phone(737)-289-0835FaxN/AEmployees1Year FoundedN/APrice Target and Rating Average Price Target for Telomir Pharmaceuticals$15.00 High Price Target$15.00 Low Price Target$15.00 Potential Upside/Downside+719.7%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$16.53 million Net MarginsN/A Pretax MarginN/A Return on Equity-2,009.40% Return on Assets-1,009.72% Debt Debt-to-Equity RatioN/A Current Ratio0.75 Quick Ratio0.75 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.02 per share Price / Book91.50Miscellaneous Outstanding Shares29,760,000Free FloatN/AMarket Cap$54.46 million OptionableN/A Beta-0.67 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:TELO) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredDebt Crisis Warning: How to Protect Your Wealth Before August 31stOn August 31st, the U.S. runs out of “extraordinary measures” to avoid default—and Washington insiders are alr...American Alternative | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredGuess Who the Gvt Could Partner With Next?The Government Just Made a $400M Bet. Who's Next? A $100 trillion wealth shift is quietly underway... and t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telomir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.